Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
43.2M
-
Shares change
-
-3.46M
-
Total reported value, excl. options
-
$154M
-
Value change
-
-$13.7M
-
Put/Call ratio
-
0.29
-
Number of buys
-
58
-
Number of sells
-
-53
-
Price
-
$3.56
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q4 2024
140 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2024.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.2M shares
of 120M outstanding shares and own 35.96% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (9.81M shares), BlackRock, Inc. (6M shares), VANGUARD GROUP INC (4.35M shares), VR Adviser, LLC (2.63M shares), FRANKLIN RESOURCES INC (2.13M shares), GEODE CAPITAL MANAGEMENT, LLC (1.65M shares), MPM BIOIMPACT LLC (1.61M shares), STATE STREET CORP (1.5M shares), Janney Montgomery Scott LLC (984K shares), and Blue Owl Capital Holdings LP (900K shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.